Cargando…
Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia
Hemophilia is characterized by a deficiency in coagulation factors VIII or IX. The general standard of care for severe hemophilia is frequent intravenous recombinant or plasma-derived factor replacement to prevent bleeding. While this treatment is effective in preventing bleeding, frequent infusions...
Autores principales: | Thornburg, Courtney D., Simmons, Dana H., von Drygalski, Annette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432364/ https://www.ncbi.nlm.nih.gov/pubmed/37490225 http://dx.doi.org/10.1007/s40259-023-00615-4 |
Ejemplares similares
-
Etranacogene dezaparvovec for hemophilia B gene
therapy
por: Thornburg, Courtney D.
Publicado: (2021) -
Gene Therapy for Hemophilia A: A Mixed Methods Study of Patient Preferences and Shared Decision-Making
por: Limjoco, Jacqueline, et al.
Publicado: (2023) -
Treatment adherence in hemophilia
por: Thornburg, Courtney D, et al.
Publicado: (2017) -
Knee Fat Pad Volumes in Patients with Hemophilia and Their Relationship with Osteoarthritis
por: von Drygalski, Annette, et al.
Publicado: (2017) -
Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics
por: Zhou, Jenny Y., et al.
Publicado: (2019)